

**TBScience2018**

23 &amp; 24 October 2018

Venue: Marriott Hotel, The Hague, The Netherlands

23-Oct

Day 1 Keynote speaker 1	time start	time end	Title	presenter	Timing (min)	time gap
	8:00	8:30	Welcome and registration		30	
	8:30	9:00	<b>TB research global agenda: needs and priorities</b>	Soumya Swaminathan, Paediatrician and Clinical Scientist	30	
<b>Plenary session 1</b>			<b>TB treatment shortening</b>	<b>Chair: Frank Cobelens and Rada Savic</b>		
subtopic 1a	9:00	9:20	Introductory WHO speaker: key questions, latest TB (MDR) epi data, latest new drug trial / treatment results from new regimens	Matteo Zignol, Scientist (WHO)	20	
subtopic 1b	9:20	9:40	New strategies and models to find novel TB drug targets: in which direction does basic science point?	Wilbert Bitter, Professor of Molecular and Medical Microbiology, VU University	20	
subtopic 1c	9:40	10:00	Animal models focusing on treatment shortening strategies: potential and future directions	Deepak Kaushal, Professor of Microbiology & Immunology (Tulane)	20	
	10:00	10:20	Mathematical modelling focusing on treatment shortening strategies: potential and future directions	Emily Kendall, Johns Hopkins University	20	
	<b>10:20</b>	<b>10:40</b>	<b>Coffee and tea break and with group photograph</b>		20	
subtopic 1e	10:40	11:00	Within-host evolution of <i>M. tuberculosis</i> : implications for drug resistance, treatment outcome, and TB transmission	Bouke de Jong (University Antwerp)	20	
subtopic 1f	11:00	11:20	Perspective: is a universal short TB treatment regimen possible? What are issues and barriers?	Frank Cobelens (UvA)	20	
	11:20	11:40	Short panel discussion	Michael Rich, Cathy Bansbach, Payam Nahid, Mel Spigelman	20	
subtopic 1g	11:40	12:00	New approaches to developing tests to monitor the response to treatment and stratification of hosts: what studies are needed?	Gerhard Walzl, Division Head: Molecular Biology and Human Genetics (SUN)	20	
subtopic 1h	12:00	12:20	Can we stratify slow versus fast converters: experience from Tanzanian studies	Martin Boeree, associate professor in Clinical Tuberculosis and other Mycobacterial Diseases. (Radbc	20	
	<b>12:20</b>	<b>13:05</b>	<b>Lunch break</b>		45	
	13:05	13:25	TB ReFLECT meta-analysis of all key FQ treatment shortening trials	Rada Savic (UCSF)	20	
subtopic 1i	13:25	13:45	The CURE-TB Strategy Trial concept on stratified medicine trials in active TB	Payam Nahid (professor UCSF) and Patrick Phillips	20	
<b>Parallel session 2</b>			<b>Parallel session on reducing transmission: what is the scientific basis behind the reduction of transmission and the initiation of appropriate therapy?</b>	<b>Chair: Michael Kimerling and Paula Fujiwara</b>		
subtopic 2a	14:00	14:20	How can next generation sequencing of TB be used to reduce transmission by improved diagnostics or by improved epidemiological understanding of TB	Sebastien Gagneux, Associate Professor of Infection Biology, (Swiss TPH)	20	
subtopic 2b	14:20	14:40	How can we translate NGS data to TB treatment shortening?	Jeff Tornheim, Assistant Professor of Medicine, (JHS)	20	
subtopic 2c	14:40	15:00	How does transmission take place? How do we identify the most transmitting patients?	Robin Wood, CEO (Desmond Tutu HIV Center)	20	
	15:00	15:20	Addressing institutional amplifiers of tuberculosis transmission	Jason Andrews, Assistant Professor of Medicine (Infectious Diseases (Stanford University)	20	
	<b>15:20</b>	<b>15:40</b>	<b>Coffee and tea break</b>		20	
subtopic 2d	15:40	16:00	Do a/oligosymptomatic incipient TB patients contribute to transmission?	Hanif Esmail (Oxford)	20	
abstracts	16:00	16:45	3-4 abstract oral presentations		45	
<b>Parallel session 3</b>			<b>Parallel session highlighting the latest developments in the TB Vaccine area</b>	<b>Chair: Richard White and Tom Ottenhoff</b>		
subtopic 3a	14:00	14:20	Pipeline of vaccines against TB in pre-clinic and clinic.	Georges Thiry	20	
	14:20	14:40	The potential epidemiological impact of new TB vaccines	Rebecca Harris, Assistant Professor, of Infectious Disease Modelling and Epidemiology, LSHTM	20	
subtopic 3b	14:40	15:00	Recent clinical vaccine developments including the BCG revaccination POI trial	Mark Hatherill, Director, SATVI	20	
	15:00	15:20	M72 prevention of disease trial : results of the primary analysis	Marie-Ange Demoitie, TB Vaccine Project Leader, Vaccines Discovery & Development, GSK	20	
	<b>15:20</b>	<b>15:40</b>	<b>Coffee and tea break</b>		20	
panel discussion	15:40	16:20	Topic TBC. Eg BCG revaccination: what should we do now? One pro (5 min) and one counter (5 min) presentation: Willem Hanekom and Helen McShane?	Aeras (Ginsberg), TBVI (Thiry), Hatherill, Vekemens, McShane, BMGF (Willem Hanekom)	40	
subtopic 3c	16:20	16:40	Newest data on RhCMV based TB vaccines in NHP, and steps towards clinical testing	Louis Picker, Oregon (OHSU) <b>(BY SKYPE)</b>	20	
	16:40	17:00	Newest data on iv administered BCG in NHP models	Bob Seder (NIAID, NIH)	20	
	17:00	17:20	Pulmonary BCG vaccination shows improved efficacy including prevention of infection and a unique local immune profile in NHP	Frank Verreck (BPRC)	20	
abstracts	17:20	17:40	2 abstract oral presentations	TBD by abstract review	25	

Parallel session 4 "TSRU"		Overall theme: Innovations in the production and use of surveillance data		Chair: Martien Borgdorff and Edine Tiemersma		
Parallel session 4a		What's the use of infection testing?				
	14:00	14:20	"History of infection testing, and rationale for WHO decision to drop recommendation to stop using..."	Philippe Glaziou, senior epidemiologist, WHO	20	
	14:20	14:40	"Update on current and new tools for infection testing"	Madhu Pai, Director, McGill Global Health Programs	20	
	14:40	15:00	"What could we use infection testing for? (trends, subnational burden estimation, ....)"	Pete Dodd	20	
	15:00	15:20	1-2 abstracts		20	
	<b>15:20</b>	<b>15:40</b>	<b>Coffee and tea break</b>		20	
	15:40	16:00	Discussion		20	
Parallel session 4b		Innovation in subnational burden estimation				
	16:00	16:20	"Subnational burden estimation in Indonesia, using prevalence distribution method"	Mohammad Noor Farid, Researcher. National Institute of Health Research and Development. Ministry of Health	20	
	16:20	16:40	"Subnational burden estimation in Brazil"	Nick Menzies, Assistant Professor of Global Health, Harvard Center for Health Decision Science	20	
	16:40	17:00	"Subnational burden estimation using the MATCH analytical framework"?	Mirjam Bakker, Team leader Epidemiology (KIT)	20	
	17:00	17:20	1-2 abstracts		20	
	17:20	17:50	Discussion + closing		30	
<b>24-Oct-18</b>						
Day 2	time start	time end	Title	presenter	Timing (min)	time gap
	8:00	8:30	Registration		30	
	8:30	8:35	Welcome day 2		5	
Plenary session 4		Mtb infection: acquisition, control and clearance		Chair: Michael Kimerling and ?		
subtopic 4a	8:35	8:55	Novel PET/CT imaging approaches reveal dynamics and spectrum of latent TB	Gerhard Walzl (SUN)	20	
subtopic 4c	8:55	9:15	New developments in refining and testing prospective Correlates of Risk of developing TB	Tom Scriba (UCT)	20	
subtopic 4d	9:15	9:35	Targeted TB screening for treatment and prevention by host biomarker stratification	Mark Hatherill (UCT)	20	
subtopic 4e	9:35	9:55	Factors controlling susceptibility to TB disease progression: HIV	Robert Wilkinson	20	
	9:55	10:15	Factors controlling susceptibility to TB disease progression: other viral coinfections including CMV	Helen Fletcher (LSHTM)	20	
	10:15	10:35	The effect of diabetes on TB susceptibility and outcome	Reinout van Crevel, Professor in Global Health and Infectious Diseases (Radboud University Medical Center)	20	
	<b>10:35</b>	<b>10:50</b>	<b>Coffee and tea break</b>		15	
subtopic 4f	10:50	11:10	Harnessing inflammation and trained immunity for TB vaccination: what distinguishes protective from harmful inflammation?	Mihai Netea, heads the division of Experimental Medicine, Department of Internal Medicine at the Radboud University Medical Center	20	
	11:10	11:30	Mycobacterial Growth Inhibition is associated with trained innate immunity	Simone Joosten, senior Reseacher (LUMC)	20	
subtopic 4g	11:30	11:50	BCG revaccination trial data suggest ability to clear Mtb infection in humans: implications. TB vaccine prevention of infection trial results	Elisa Nemes (UCT)	20	
subtopic 4h	11:50	12:10	New hypotheses for the natural history of TB using models combining data from modelling, epidemiological, clinical and basic research	Rein Houben (LSHTM)	20	
	12:10	12:30	Closing remarks		20	

"Targeted TB screening for treatment and prevention by host biomarker stratification"